zomedica corp (NYSE American:ZOM) The 1 analysts offering 12-month price forecasts for Zomedica Corp have a median target of 1.20, with a high estimate of 1.20 and a low estimate of 1.20 The median estimate represents a +358.19% increase from the last price of 0.26.
Will ZOM recover?
ZOM stock will likely struggle to recover in price over the next few months It’s going to be awhile before this early stage company will again have the chance to prove itself to investors. Having said that, investors with a high appetite for risk, and a willingness to go against the grain, may want to buy today.
Why is ZOM dropping?
CEO Robert Cohen said the move was precipitated by ” changes at our current distributor that we believe have impacted its ability to market our products effectively” Those words likely startled investors, many of whom decided to sell their shares. Zomedica’s stock price dropped sharply on Thursday.
Should I sell my Zomedica stock?
Considering the 90-day investment horizon and your highly speculative risk level, our recommendation regarding Zomedica Pharmaceuticals Corp is ‘ Strong Sell ‘.
Is Zomedica being shorted?
What is Zomedica’s current short interest? Short interest is the volume of Zomedica shares that have been sold short but have not yet been covered or closed out. As of June 15th, traders have sold 101,490,000 shares of ZOM short. 10.52% of Zomedica’s shares are currently sold short.
Is Zomedica a real company?
About us. Zomedica (NYSE American:ZOM) is a veterinary health company focused on meeting the needs of clinical veterinarians in ways that promote both patient and practice health.
Is TherapeuticsMD a good stock to buy?
TherapeuticsMD has received a consensus rating of Hold The company’s average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.
Does Zom reverse split?
Despite now generating revenue from the sale of its Truforma diagnostics system, Zomedica is valued at nearly 70 times Wall Street’s projected sales for 2023. It’s also nowhere near profitability. It’s a strong candidate to enact a reverse split sometime over the next 12 to 18 months.
Is Sundial growers a buy?
Following the q3 earnings report, Sundial shares experienced a strong rally. However, even though SNDL is worth just over 50 cents and is under pressure to pass the $1-per-share level to remain in compliance with Nasdaq, here are three reasons why buying the stock ahead of earnings could be a good deal.
Is Acasti Pharma a good stock to buy?
Acasti Pharma has received a consensus rating of Buy The company’s average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Will ZOM price go up?
There is potential for a short term uptick in the Zom stock price , especially as the active weekly candle is mildly bullish. The relative strength index is relatively oversold and has been for quite some time.
What does ZOM company do?
Zoom Video Communications, Inc. develops a people-centric cloud service that transforms real-time collaboration experience The Company offers unified meeting experience, a cloud service that provides a 3-in-1 meeting platform with HD video conferencing, mobility, and web meetings.
Who is shorting AMC?
Bank of America Is Shorting AMC Stock. Bank of America is on the list of the top 10 institutions shorting AMC stock. BofA is known for being an untrustworthy bank for the people, so it comes as no surprise.
What is fintel io?
About Fintel.io: Fintel.io is a leading equity research platform designed to help data-driven investors make better investing decisions Fintel provides deep an. Fintel currently tracks over 30,000 funds and over 63,000 securities traded worldwide.